Join to View Full Profile
12605 E 16th AveAurora, CO 80045
Phone+1 303-724-9238
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Lentz, MD is an oncologist in Aurora, Colorado. He is currently licensed to practice medicine in Colorado and Illinois. He is affiliated with University of Colorado Hospital.
Education & Training
Vanderbilt University School of MedicineClass of 2016
Certifications & Licensure
CO State Medical License 2019 - 2027
IL State Medical License 2016 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Oligometastatic pancreatic cancer: current state of management and emerging therapies.Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar, Christopher H Lieu, Marco Del Chiaro
The Oncologist. 2025-06-04 - 1 citationsA Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.Robert W Lentz, Tyler J Friedrich, Patrick J Blatchford, Kimberly R Jordan, Todd M Pitts
Clinical Cancer Research. 2024-09-03 - Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.Benjamin E Ueberroth, Christopher H Lieu, Robert W Lentz
Journal of Gastrointestinal Cancer. 2024-09-01
Press Mentions
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)June 3rd, 2025- Updated Data from Phase I Study of Antibody-Drug Conjugate EBC-129 ReleasedJune 3rd, 2025
- Experimental Drug Development Centre Reveals Updated Phase 1 Data on Antibody-Drug Conjugate EBC-129 at ASCO 2025June 3rd, 2025
